Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as psychosis and agitation can cause significant patient and caregiver distress and contribute to nursing home placement. Owing to the lack of approved therapies to manage these symptoms in AD patients, physicians prescribe an array of drugs from a range of drug classes, but the drugs are often associated with unwanted side effects and safety risks. This study examines the drug and class-level prescribing patterns for key neuropsychiatric therapies—antipsychotics, mood stabilizers, anxiolytics, and benzodiazepines—in patients diagnosed with AD to provide context for developers of new brands that may enter a mostly generic but entirely off-label market arena.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Antipsychotics (e.g., quetiapine), mood stabilizers (e.g., divalproex sodium), anxiolytics (e.g., buspirone), benzodiazepines (e.g., alprazolam)
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group. She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.